| 尼妥珠单抗联合奈达铂和三维适形同步放化疗对鼻咽癌的疗效、安全性及对TGF-β1、S100A8和S100A9的影响 |
| 投稿时间：2014-05-24 修订日期：2014-06-24 点此下载全文 |
| 引用本文：李丹,白燕,谢可,敖睿.尼妥珠单抗联合奈达铂和三维适形同步放化疗对鼻咽癌的疗效、安全性及对TGF-β1、S100A8和S100A9的影响[J].医学研究杂志,2015,44(11):136-139 |
| DOI：
10.11969/j.issn.1673-548X.2015.11.038 |
| 摘要点击次数: 832 |
| 全文下载次数: 847 |
|
|
| 中文摘要:目的 探讨尼妥珠单抗联合奈达铂和三维适形同步放化疗对鼻咽癌的疗效、安全性及对TGF-β1、S100A8和S100A9的影响。方法 选取2009年4月~2012年2月间笔者医院诊治的60例鼻咽癌患者为研究对象,依据治疗方案的不同随机将患者分为奈达铂-三维适形同步放化疗组(对照组)和尼妥珠单抗联合奈达铂-三维适形同步放化疗组(观察组),每组各30例。观察两种治疗方式的临床近、远期疗效和不良反应发生情况,并对比TGF-β1、S100A8和S100A9的含量变化。结果 治疗后两组患者的病情均出现不同的缓解,观察组患者共21例出现缓解,总体有效率为70.00%,明显高于对照组(12/30, 40.00%, P<0.05);而且除了对照组恶性呕吐发生率明显高于观察组之外,两组患者各种不良反应发生率比较均无统计学意义(P>0.05);观察组患者的生存时间亦明显高于对照组(P<0.05)。此外,治疗后两组患者的TGF-β1、S100A8和S100A9含量较治疗前均明显降低,而且观察组的下降幅度明显优于对照组,差异具有统计学意义(P<0.05)。结论 尼妥珠单抗联合奈达铂-三维适形同步放化疗方案具有良好的临床近期和远期疗效,并可明显改善TGF-β1、S100A8和S100A9含量变化。 |
| 中文关键词:尼妥珠单抗 奈达铂 鼻咽癌 TGF-β1 S100A8 S100A9 |
| |
| Efficacy and Safety of Nimotuzumab Combined with Nedaplatin and Three-dimensional Conformal Concurrent Radiotherapy for Nasopharyngeal Cancer Chemotherapy and the Impact of TGF-β1, S100A8 and S100A9. |
|
|
| Abstract:Objective To investigate efficacy and safety of nimotuzumab combined with nedaplatin and three-dimensional conformal concurrent radiotherapy for nasopharyngeal cancer chemotherapy and the impact of TGF-β1, S100A8 and S100A9. Methods The 60 cases of nasopharyngeal carcinoma patients were recruited from April 2009 to February 2012 in our hospital for this study, and randomly divided patients into treatment programs nedaplatin-dimensional conformal chemoradiotherapy group(control group) and nimotuzumab joint nedaplatin-dimensional conformal chemoradiotherapy group(observation group), 30 cases in each. We Compared changes on clinical observation of treatment, the long-term efficacy and adverse events, and to in TGF-β1, S100A8 and S100A9 levels. Results After treatment, both groups of patients with the disease had different mitigation, and 21 cases in the observation group were of remission and the overall response rate was 70.00% which was significantly higher than the controls(12/30, 40.00%, P<0.05). The incidence of malignant vomiting in control group was significantly higher than in the observation group, whereas there was no significant difference in the other incidence of various adverse reactions(P>0.05). The survival time in the observation group was significantly higher than the controls(P<0.05). After treatment, the levels of TGF-β1, S100A8 and S100A9 were lower than before treatment, and the decline in the observation group was obvious than the control group(P<0.05). Conclusion Nimotuzumab combined with nedaplatin, dimensional conformal chemoradiotherapy scheme had good short-term and long-term clinical efficacy, and could significantly improve the TGF-β1, S100A8 and S100A9 content changes. |
| keywords:Nimotuzumab Nedaplatin Nasopharyngeal carcinoma TGF-β1 S100A8 S100A9 |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
